OakChart

Cognition Therapeutics Inc

CGTXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.6773+0.0071 (1.06%)
2026-11-12 02:32 CET
Market cap
64.41 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-15.99 USD m
Free cash flow, TTM
-15.31 USD m
EPS diluted, TTM
-0.18
P/E
-
Compare

Price

CGTX against its 20, 50 and 200-day averages
2050200earnings
1.001.505.9M11.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CGTXclose 0.6820-day 0.7150-day 0.86200-day 1.040.6852w high

62.6% under the 52-week high of 1.81 on 3 Dec 2025. 52-week low 0.55 on 30 Mar 2026. Last 15 sessions, 30.9% high to low

Volume 0.41× normal · the line is the 50-bar volume average

Profile

CGTX
52-week range, 10% of the way up
0.551.81

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Employees14
IPOOct 08, 2021
Beta1.81
ATR, 14d0.06
Rel volume0.41
Short float7.91%
Insider own8.11%
Inst own17.29%

Snapshot

6 groups

Valuation

Index-
Market Cap64.42M
Enterprise Value33.43M
Income-15.99M
Sales0.00M
Book/sh0.31
Cash/sh0.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPOOct 08, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.20
P/C2.05
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.68
Current Ratio6.68
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.18
EPS next Y-0.18
EPS next Q-0.05
EPS this Y40.62%
EPS next Y2.63%
EPS next 5Y4.35%
EPS past 3/5Y24.09% 10.12%
Sales past 3/5Y- -
EPS Y/Y TTM62.99%
Sales Y/Y TTM-
EPS Q/Q31.01%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.40.03% -

Ownership

Insider Own8.11%
Insider Trans0.00%
Inst Own17.29%
Inst Trans-0.21%
ROA-40.90%
ROE-48.60%
ROIC-53.88%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-4.49%
SMA50-21.15%
SMA200-34.73%
Trades-

Technical

Shs Outstand95.10M
Shs Float87.39M
Short Float7.91%
Short Ratio14.32
Short Interest6.92M
52W High1.81 -62.58%
52W Low0.55 23.12%
Volatility8.47% 7.95%
ATR (14)0.06
RSI (14)37.34
Beta1.81
Rel Volume0.41
Avg Volume483.03K
Volume200,264

Performance

Perf Week-0.88%
Perf Month-15.52%
Perf Quarter-34.87%
Perf Half Y-43.56%
Perf YTD-49.83%
Perf Year-61.30%
Perf 3Y-36.40%
Perf 5Y-94.42%
Perf 10Y-
Recom1.00
Target Price3.33
Prev Close0.67
Price0.68
Change %1.06%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Dec 19, 2024UpgradeRB. Riley SecuritiesNeutral → Buy$1 → $1.50+121.5%
Jul 30, 2024DowngradeCCantor FitzgeraldOverweight → Neutral
Nov 03, 2021InitiatedOOppenheimerOutperform$22+3,148.2%
Nov 03, 2021InitiatedRB. Riley SecuritiesBuy$27+3,886.4%

Peers

Mkt cap
TickerCompanyMkt cap
AVXLAnavex Life Sciences Corp98.26M
ANVSAnnovis Bio Inc36.41M
ABOSAcumen Pharmaceuticals Inc16.64M
PMNProMIS Neurosciences Inc33.72M
INMBINmune Bio Inc34.05M
ACADAcadia Pharmaceuticals Inc3.17B
ALECAlector Inc391.55M
PRTAProthena Corp Plc448.28M
COYACoya Therapeutics Inc75.30M
DNLIDenali Therapeutics Inc3.16B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Doyle John BrendanChief Financial OfficerApr 16 '26Buy1.1310,00011,300627,509Apr 20 04:18 PM
Ricciardi LisaCEO & PresidentApr 16 '26Buy1.109,17510,0921,715,851Apr 20 04:16 PM
Caggiano AnthonyChief Medical OfficerApr 16 '26Buy1.1110,00011,100874,906Apr 20 04:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
IBRNiShares Neuroscience and Healthcare ETFAUM: 8.68M

News

latest 14 of 200
  • Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
  • Cognition Therapeutics Narrows Loss And Lands FDA Alignment On A Leaner DLB Phase 3, But The Pivotal Trial Is Still Unfunded (Earnings Whispers) -7.01%
  • Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update (GlobeNewswire)
  • Cognition Therapeutics Heads Into Q3 With A Wider Loss Expected And A Sub-Dollar Stock (Earnings Whispers)
  • Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 (GlobeNewswire)
  • Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies (GlobeNewswire) -6.16%
  • Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development (InvestorsHub) -6.44%
  • Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 (GlobeNewswire)
  • Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB (GlobeNewswire)
  • Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
  • Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update (GlobeNewswire) +6.60%
  • Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit (GlobeNewswire) -6.42%
  • Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis But CGTX Stock Just Crashed 33% (Stocktwits) -38.18%
  • Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.040-0.067-0.2500.000.003
2026Q22026-08-06-0.040-0.063-0.0430.000.003
2026Q12026-05-07-0.050-0.068-0.0510.000.004
2025Q42026-03-26-0.037-0.078-0.0380.000.004
2025Q32025-11-06-0.060-0.090-0.0630.000.004
2025Q22025-08-07-0.110-0.105-0.1060.000.004
2025Q12025-05-07-0.140-0.116-0.1370.000.005
2024Q42025-03-20-0.189-0.170-0.1690.000.006
2024Q32024-11-13-0.250-0.197-0.2460.000.006
2024Q22024-08-08-0.180-0.236-0.1760.000.007
2024Q12024-05-07-0.270-0.247-0.2710.000.003
2023Q42024-03-26-0.270-0.320-0.2650.000.004
2023Q32023-11-02-0.220-0.237-0.2220.000.004
2023Q22023-08-08-0.160-0.177-0.1600.000.004
2023Q12023-05-04-0.210-0.177-0.2120.000.003
2022Q42023-03-23-0.200-0.225-0.1790.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-3.130-1.640-0.7310.000.00
2022FY-0.910-0.920-0.7380.000.00
2023FY-0.860-0.928-0.8590.000.00
2024FY-0.860-0.822-0.8550.000.00
2025FY-0.320-0.390-0.8600.000.00
2026FY--0.190--0.00
2027FY--0.185--0.00
2028FY--0.280--0.00
2029FY--0.240--45.10
2030FY--0.190--112.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-053000.000.000.00
2026Q4S2026-08-073000.000.000.00
2026Q4S2026-05-083000.000.000.00
2026Q4S2026-03-313000.000.000.00
2026Q4S2026-03-272000.000.000.00
2026Q4S2026-03-261000.000.000.00
2026Q4S2025-11-202000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4E2026-11-06330-0.05-0.06-0.04
2026Q4E2026-11-05320-0.05-0.06-0.05

Estimate history

EPS, annual-0.399-0.55-0.731-0.738-0.859-0.855-0.323-0.1758
Period2019202020212022202320242025TTM
EPS, quarterly-0.246-0.169-0.137-0.106-0.063-0.038-0.051-0.043-0.044
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.93721.93722.2328.99232.16559.85588.90495.101
Period2019202020212022202320242025MRQ
Shares, quarterly40.80659.85561.97564.96388.26888.90489.35495.05695.101
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.220.230.270.250.230.090.100.08
Gross Profit-0.22-0.23-0.27-0.25-0.23-0.09-0.10-0.08
Selling, General and Administrative Excl. Other37.3947.5753.7050.4743.3228.5017.3117.75
Research and Development27.3337.1941.6837.2030.3218.5712.8914.38
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-37.60-47.80-53.97-50.72-43.55-28.60-17.41-17.83
Interest Expense0.010.010.030.030.030.891.751.02
Unusual Expense0.000.000.000.000.00-0.42-0.070.24
Net Income Before Taxes-15.99-23.49-33.97-25.79-21.40-11.72-7.84-4.84
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-15.99-23.49-33.97-25.79-21.40-11.72-7.84-4.84
Net Income From Continuing Operations-15.99-23.49-33.97-25.79-21.40-11.72-7.84-4.84
Net Income-15.99-23.49-33.97-25.79-21.40-16.25-12.07-8.76
EPS (Recurring)-0.17-0.32-0.86-0.86-0.74-0.74-0.55-0.39
EPS (Basic, Before Extraordinaries)-0.18-0.32-0.85-0.86-0.74-0.73-0.55-0.40
EPS (Diluted)-0.18-0.32-0.85-0.86-0.74-0.73-0.55-0.40
EBITDA-37.39-47.57-53.70-50.47-43.32-28.50-17.31-17.75
Non-Operating Income (Expense)21.6324.3220.0224.9622.1817.3611.2514.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.352.093.754.353.575.180.470.36
Shares Outstanding95.1088.9059.8532.1728.9922.2321.9421.94
Market Capitalization64.4164.4129.1456.2750.34132.42126.14-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.060.070.060.060.060.040.07
Gross Profit-0.03-0.06-0.07-0.06-0.06-0.06-0.04-0.07
Selling, General and Administrative Excl. Other7.347.688.7513.616.3113.9213.7310.65
Research and Development5.095.046.0511.153.7711.4810.798.15
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.38-7.74-8.82-13.67-6.38-13.98-13.78-10.72
Interest Expense0.000.000.010.01-0.000.010.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.14-3.93-4.57-3.34-4.93-6.73-8.48-7.84
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.14-3.93-4.57-3.34-4.93-6.73-8.48-7.84
Net Income From Continuing Operations-4.14-3.93-4.57-3.34-4.93-6.73-8.48-7.84
Net Income-4.14-3.93-4.57-3.34-4.93-6.73-8.48-7.84
EPS (Recurring)-0.04-0.04-0.05-0.04-0.06-0.11-0.14-0.17
EPS (Basic, Before Extraordinaries)-0.04-0.04-0.05-0.04-0.06-0.11-0.14-0.17
EPS (Diluted)-0.04-0.04-0.05-0.04-0.06-0.11-0.14-0.17
EBITDA-7.34-7.68-8.75-13.61-6.31-13.92-13.73-10.65
Non-Operating Income (Expense)3.233.814.2510.331.457.255.302.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.350.320.330.360.520.620.590.53
Shares Outstanding95.1095.0689.3588.9088.2764.9661.9759.85
Market Capitalization64.41102.9267.86119.17119.1019.2126.0829.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments37.0025.0129.9241.5654.725.192.89
Short Term Receivables9.922.691.283.672.271.154.12
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.071.863.022.412.000.570.15
Total Current Assets47.9929.5534.2247.6558.996.917.16
Net Property, Plant & Equipment0.400.680.941.050.140.210.30
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.000.000.00-0.000.000.00
Other Assets0.000.000.001.730.000.000.00
Total Assets48.3930.2335.1650.4259.147.127.46
Short Term Debt Incl. Current Port. of LT Debt0.440.190.170.150.000.000.00
Accounts Payable1.121.983.693.224.172.002.36
Other Current Liabilities12.368.966.304.433.701.251.32
Total Current Liabilities13.9211.1410.177.797.863.253.68
Long Term Debt0.200.340.001.690.0068.2259.82
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.520.690.003.832.37
Total Liabilities14.1211.4810.6910.187.8675.3065.88
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity34.2718.7524.4740.2551.27-68.18-58.42
Total Shareholders Equity34.2718.7524.4740.2551.27-68.18-58.42
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity34.2718.7524.4740.2551.27-68.18-58.42
Total Liabilities & Stockholders Equity48.3930.2335.1650.4259.147.127.46
Book Value Per Share0.390.310.761.392.31-3.11-2.66
Tangible Book Value Per Share0.390.310.761.392.31-3.11-2.66
Full-Time Employees142828252122-
Price to Book Ratio2.201.981.951.282.74-1.53-
Return on Assets-59.75-103.89-60.26-39.06-35.37-107.55-
Return on Equity-88.60-157.19-79.69-46.76---
Return on Invested Capital-68.15-177.93-105.37-51.02-22.85-20,628.95-345.36
Quick Ratio3.452.653.376.117.502.131.94
Current Ratio3.452.653.376.117.502.131.94

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-15.99-23.49-33.97-25.79-21.40-11.72-7.84-4.84
Depreciation0.220.230.270.250.230.090.100.08
Other Funds (Non Cash)1.382.133.944.673.575.151.241.09
Funds from Operations-14.39-21.13-29.76-20.86-17.59-6.47-6.50-3.67
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.90-3.461.294.85-0.942.843.070.57
Cash from Operating Activities-15.29-24.59-28.47-16.02-18.53-3.63-3.43-3.10
Capital Expenditures-0.020.00-0.00-0.15-0.17-0.03-0.01-0.14
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.010.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.010.01-0.00-0.15-0.17-0.03-0.01-0.14
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock7.5937.0924.435.336.9453.470.050.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock7.5937.0924.435.336.9453.470.050.00
Proceedsfrom Stock Options7.5437.0224.355.335.3253.160.030.00
Issuance or Reduction of Debt, Net-0.38-0.35-0.74-0.81-1.40-0.275.722.79
Change in Long Term Debt-0.35-0.35-0.74-0.81-1.40-0.275.722.84
Issuance of Long Term Debt0.000.000.000.000.000.005.722.84
Reduction of Long Term Debt-0.35-0.35-0.74-0.81-1.40-0.270.000.00
Net Financing Active Other Cash Flow-0.25-0.16-0.130.000.000.000.000.00
Other Financing Activities Uses-0.25-0.16-0.130.000.000.000.000.00
Cash from Financing Activities6.9536.5723.574.525.5553.205.762.79
Exchange Rate Effect--0.000.00-0.00-0.01-0.02-0.06
Net Change in Cash-8.3511.99-4.91-11.64-13.1649.532.30-0.51
Free Cash Flow-15.31-24.59-28.48-16.16-18.70-3.66-3.44-3.24
Preferred Dividends (Cash Flow)-0.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments31.4834.7631.2337.0039.8211.56
Short Term Receivables2.502.953.669.921.906.29
Inventories0.000.000.000.000.000.00
Other Current Assets0.260.590.931.071.161.21
Total Current Assets34.2438.3035.8147.9942.8819.05
Net Property, Plant & Equipment0.560.600.330.400.510.57
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets34.8038.9036.1448.3943.4019.62
Short Term Debt Incl. Current Port. of LT Debt0.090.170.290.440.170.24
Accounts Payable0.450.673.851.120.830.77
Other Current Liabilities4.594.611.9112.365.6611.35
Total Current Liabilities5.135.456.0513.926.6512.36
Long Term Debt0.400.420.180.200.210.23
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.535.876.2314.126.8712.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity29.2833.0229.9134.2736.537.03
Total Shareholders Equity29.2833.0229.9134.2736.537.03
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity29.2833.0229.9134.2736.537.03
Total Liabilities & Stockholders Equity34.8038.9036.1448.3943.4019.62
Book Value Per Share0.310.350.330.390.410.11
Tangible Book Value Per Share0.310.350.330.390.410.11
Full-Time Employees---14--
Price to Book Ratio2.203.441.973.2612.481.56
Return on Assets-40.90-57.33-65.65-59.75-78.86-122.22
Return on Equity-48.60-83.76-92.82-88.60-109.73-219.68
Return on Invested Capital-13.97-11.76-15.19-9.70-13.42-92.78
Quick Ratio6.687.035.923.456.441.54
Current Ratio6.687.035.923.456.441.54

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.14-3.93-4.57-3.34-4.93-6.73
Depreciation0.030.060.070.060.060.06
Other Funds (Non Cash)0.350.300.340.400.520.62
Funds from Operations-3.76-3.58-4.17-2.88-4.35-6.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.510.53-1.38-0.55-1.300.43
Cash from Operating Activities-3.26-3.05-5.54-3.44-5.65-5.62
Capital Expenditures0.00-0.020.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.010.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.020.000.010.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.056.740.040.7633.990.88
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.056.740.040.7633.990.88
Proceedsfrom Stock Options0.056.740.000.7533.930.88
Issuance or Reduction of Debt, Net-0.08-0.12-0.11-0.07-0.04-0.12
Change in Long Term Debt0.000.000.00-0.350.000.12
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.350.000.12
Net Financing Active Other Cash Flow0.00-0.01-0.16-0.08-0.04-0.01
Other Financing Activities Uses0.00-0.01-0.16-0.08-0.04-0.01
Cash from Financing Activities-0.036.61-0.230.6033.920.75
Net Change in Cash-3.293.54-5.78-2.8228.27-4.87
Free Cash Flow-3.26-3.07-5.54-3.44-5.65-5.62

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
No short interest data.

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-03SEC
2026-10-228-KCurrent report2026-10-22SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-17SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-03-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-03-028-KCurrent report2026-03-02SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-15SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-15SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-0432.49K300
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BIOS Capital Management, LP6.70%
DAVENPORT & Co LLC4.47%
VANGUARD CAPITAL MANAGEMENT LLC3.84%
BlackRock, Inc.1.41%
Chescapmanager LLC1.11%
GEODE CAPITAL MANAGEMENT, LLC0.96%
RENAISSANCE TECHNOLOGIES LLC0.77%
Hilton Capital Management, LLC0.61%
VANGUARD FIDUCIARY TRUST CO0.57%
CM Management, LLC0.50%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.73%
VANGUARD EXTENDED MARKET INDEX FUND0.97%
Fidelity Extended Market Index Fund0.45%
iShares Micro-Cap ETF0.31%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.12%
Schwab Total Stock Market Index Fund0.09%
VANGUARD BALANCED INDEX FUND0.04%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.04%
Gabelli Global Mini Mites Fund0.03%

OakChart. CGTX. Cached 15 minutes.

Some panels did not load: si.